<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03153488</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000547</org_study_id>
    <nct_id>NCT03153488</nct_id>
  </id_info>
  <brief_title>Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response</brief_title>
  <official_title>Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 6-month open-label, randomized control trial in adults to find out if certain
      neuromarkers can predict individual treatment response to stimulant medications for Attention
      Deficit Hyperactivity Disorder (ADHD). Males and females, ages 18-55, will be randomized to
      receive either an amphetamine or a methylphenidate formulation for their ADHD. Before
      beginning to receive medication treatment, each subject will complete an MRI scan at MIT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADHD Clinical Global Impressions Scale - Severity (CGI-S)</measure>
    <time_frame>6 months</time_frame>
    <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADHD Clinical Global Impressions Scale - Improvement (CGI-I)</measure>
    <time_frame>6 months</time_frame>
    <description>The Clinical Global Impression - Improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Connectomic Variation Prediction of Medicine Response</measure>
    <time_frame>6 months</time_frame>
    <description>Examine whether variation in baseline ADHD severity scores and functional connectivity and structural connectivity predict whether an individual ADHD patient will respond better to one of the other stimulant family treatment, both, or neither. An MRI will be completed prior to starting medication.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Methylphenidate LA (Ritalin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult subjects (ages 18-55) will be randomized to receive either Methylphenidate LA or Mixed Amphetamine Salts (XR). This dose of the stimulant will be titrated with the goal of achieving optimal response and good tolerability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mixed Amphetamine Salts XR (Adderall)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult subjects (ages 18-55) will be randomized to receive either Methylphenidate LA or Mixed Amphetamine Salts (XR). This dose of the stimulant will be titrated with the goal of achieving optimal response and good tolerability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate LA (Ritalin)</intervention_name>
    <description>Subjects will be prescribed a titrated dose of Methylphenidate LA for 6 months.</description>
    <arm_group_label>Methylphenidate LA (Ritalin)</arm_group_label>
    <other_name>Ritalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mixed Amphetamine Salts XR (Adderall)</intervention_name>
    <description>Subjects will be prescribed a titrated dose of Mixed Amphetamine Salts XR for 6 months.</description>
    <arm_group_label>Mixed Amphetamine Salts XR (Adderall)</arm_group_label>
    <other_name>Adderall</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adults ages 18-55

          -  A diagnosis of DSM-V ADHD based on clinical assessment supported by the ADHD module of
             a structured diagnostic interview

          -  Proficiency in English

          -  Right-handed

        Exclusion Criteria:

          -  Any contraindication for the use of a stimulant medication

          -  Investigator and his/her immediate family (spouse, parent, child, grandparent, or
             grandchild)

          -  Any contraindications for MRI examination (metallic implants, such as pacemakers,
             surgical aneurysm clips, or known metal fragments in the body)

          -  Women who are currently pregnant or breastfeeding, as confirmed by a urine pregnancy
             test

          -  Clinically significant abnormal baseline laboratory values, including systolic and
             diastolic blood pressure parameters above 140 and 90, respectively and resting heart
             rate outside 60-100 bpm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Biederman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Noyes</last_name>
    <phone>617-724-2551</phone>
    <email>enoyes@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexa Pulli, BS</last_name>
    <phone>617-726-4651</phone>
    <email>apulli@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Noyes</last_name>
      <phone>617-724-2511</phone>
      <email>enoyes@partners.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Biederman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Joseph Biederman, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Methylphenidate</keyword>
  <keyword>Amphetamine</keyword>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Adderall</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

